Clinical Trial Search

Primary: Number of Participants With a Complete Resolution at the Final Visit — 36; 23 Participants — p=0.0595

Primary: Adjusted Mean Percent Changes From Baseline in Soluble CD40 Ligand (sCD40L) — 223.76; 35.04; 38.88; 32.74 percent change

Primary: Number of Subjects With Anti-hepatitis B (HB) Antibody Concentrations Above the Cut-off One Month After the Booster Dose — 88; 92; 48 subjects

Primary: Mean 24-hour Reflective Total 5 Symptoms Score (T5SS) — 8.96; 8.77 points on a scale — p=0.546

Primary: Relationship Between Amiodarone Concentration in Fat Tissue and Cumulated Dose. — 0.20 Correlation coefficient R

Primary: Number of Participants Who Experienced a Primary Combined Outcome — 174; 181 participants — p=0.866

Primary: Changes From Study Period II Baseline (Week 0) to Weeks 3, 4, 6, 8, and 12 in Positive and Negative Syndrome Scale (PANSS) Total Score in Early Onset Response and Not…

Primary: Apnea-Hypopnea Index — 1.0; 1.6 apnea-hypopnea episodes per hour — p=0.9219

Primary: Verbal Pain Score — 3; 0; 0 Units on a scale — p=<0.0001

Primary: Antibody Response to Hepatitis A - Participants With a Serological Response — 182; 158 Participants — p=<0.001

Primary: Global Diagnostic Preference Between the Two Exams — 22; 21; 27; 19 Contrast-enhanced Images — p=< 0.0001

Primary: Change From Baseline in A1C at Week 24 — -0.2; -1.0; 0.0 Percent Difference

Primary: Change From Baseline in ADAS-cog+ (Alzheimer's Disease Assesment Scale - Cognitive Subpart) at Week 24 — -10.60; -4.49 points on a scale — p=< 0.0001

Primary: Percent Change in Serum Triglycerides From LOV111859/OM5 (Double-blind [DB] Study) Baseline to Week 8 of LOV111860/OM5X (1st Open-label [OL] Extension Study) and From…

Primary: Change in Baseline to Last Observation In Normalized Insulin Sensitivity Index at Low Insulin Phase Using Change in Weight as a Covariate — 0.1664; 0.1937; -0.0149…